Our analyses also demonstrated the protective role of CD3 on naive CD8+ T cells and CD3 on naive CD4+ T cells in mediating the causality between anilide medications and liver cancer, inspiring the idea of combining anilides with CD3-related immunotherapy for liver cancer treatment. The gene discussed is CD4; the disease is liver cancer.